Friday, July 10, 2026

pharma · Multiple Myeloma · Neoplasms

Teva/Actavis Generics

Teva Generics is a pharma organization headquartered in EU. Primary therapeutic focus areas include Multiple Myeloma, Neoplasms, Eosinophilic Asthma, Asthma. NovaPharmaNews links 4 clinical program(s), 0 drug profile(s),

Salt Lake City, USA HQ
1992 Founded
100 Employees
EMA registrant Type
Company details
Status
Public
HQ
Salt Lake City, USA
Founded
1992
Employees
100
Programs
4
Drugs
1
Patents
0
Clinical program

Reslizumab

Phase 3 · small molecule · Eosinophilic Asthma

Reslizumab for Eosinophilic Asthma is a Phase 3 program (small_molecule) at Teva Generics B.V with 1 ClinicalTrials.gov record(s).

← All Teva Generics B.V projects Phase 3 small molecule terminated

Internal code C38072/3085

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Teva Generics B.V
Phase
Phase 3
Modality
small_molecule
Indication
Eosinophilic Asthma
Status
terminated
Trials
1